EGFR Test Your Knowledge

Quiz

Osimertinib For Progressive EGFR-Mutated T790M-Negative NSCLC

04/25/2023

How did patients with EGFR-mutated T790M-negative non-small cell lung cancer that had progressed after treatment with TKIs and chemotherapy respond to osimertinib?

How did patients with...

04/25/2023

Oncology

Test Your Knowledge

L858R Mutation by Stage in EGFR-Mutated Lung Cancer

04/13/2023

Is there a difference in L858R mutation rates in EGFR-mutated lung cancer when stratified by stage?

Is there a difference in L858R...

04/13/2023

Oncology

Quiz

Are PD-L1 Scores Predictive of TP53 Mutation Rates?

02/13/2023

A study investigated a potential link between PD-L1 scores and TP53 tumor mutation.

A study investigated a potential...

02/13/2023

Oncology

Quiz

Quiz: Targeted Therapies for EGFR-Mutant Lung Cancer

12/02/2022

What study recently provided an additional 2 years of data to support adjuvant osimertinib as treatment of EGFR-mutant lung cancer?

What study recently provided an...

12/02/2022

Oncology

Test Your Knowledge

Quiz: Combination Therapies as Treatment Options for EGFR-Mutated Lung Cancer

11/30/2022

Which combination therapies are currently being evaluated in clinical trials as treatment options for patients with EGFR-mutated lung cancer?

Which combination therapies are...

11/30/2022

Oncology

Quiz

Quiz: Which somatic missense non-synonymous single nucleotide polymorphisms were recently determined to be putative novel rare genetic markers for NSCLC?

10/12/2022

After analyzing a selected pool of oncogenes, which somatic missense non-synonymous single nucleotide polymorphisms did a first-of-its-kind study find to be deleterious in patients with non-small cell lung cancer?

After analyzing a selected pool...

10/12/2022

Oncology

Quiz

Quiz: Amivantamab Outcomes vs Other Real-World Therapies for EGFR-Mutated NSCLC

07/25/2022

In the single-arm CHRYSALIS study, among patients with EGFR exon 20 insertion-mutated advanced NSCLC who progressed after platinum-based chemotherapy, what outcome did not improve when treated with amivantamab vs real-world therapies?

In the single-arm CHRYSALIS...

07/25/2022

Oncology

Test Your Knowledge

Quiz: Are Anti-EGF Vaccinations Effective for EGFR+ NSCLC?

02/14/2022

True or false: Anti-EGF vaccinations provide zero clinical benefit for EGFR+ NSCLC.

True or false: Anti-EGF...

02/14/2022

Oncology

Test Your Knowledge

Quiz: Does Ivonescimab Show Excellent Anti-Tumor Effects in NSCLC?

02/08/2022

True or false: Ivonescimab shows excellent anti-tumor effects in NSCLC.

True or false: Ivonescimab shows...

02/08/2022

Oncology

Test Your Knowledge

Quiz: Are EGFR-TKIs Viable With Chemo in Advanced NSCLC?

01/31/2022

True or false: EGFR-TKIs with chemo achieve clinical benefit in advanced NSCLC.

True or false: EGFR-TKIs with...

01/31/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology